Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival

Publish date:: January 6, 2021

Key clinical point: Tumor reduction after neoadjuvant therapy could be a prognostic indicator in patients who undergo surgery for pancreatic ductal adenocarcinoma.

Major finding: A reduction of 47% or more was associated with a 64% 3-year survival, compared with 32%.

Study details: A retrospective analysis of 905 patients.

Disclosures: The study was funded in part by the National Pancreas Foundation, Sky Foundation, and the Pittsburgh Liver Research Center at the University of Pittsburgh. One author disclosed receiving an honorarium from Foundation Medicine, but the rest reported having nothing to disclose.

Citation:

Das R et al. Clin Gastroenterol Hepatol. 2020 Dec 2. doi: 10.1016/j.cgh.2020.11.041.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastrointestinal Cancer

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Geography and behaviors linked to early-onset colorectal cancer survival in U.S. women,

BE: Surveillance endoscopy frequency improving but still overdone,